EGFR and non-small cell lung carcinoma: In this context, the number of clinical trials, notably those associated with neoadjuvant and/or adjuvant targeted therapy in early stage NSCLC, dropped, and this situation may slow down the development of these patients receiving care with different EGFR TKIs in the near future.